Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Sistema de administración de medicamentos y productos biocosmecéuticos altamente eficiente

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOKR20180226001
Publicado:
18/05/2018
Caducidad:
19/05/2019
Resumen:
Una bio-venture coreana ha desarrollado un nuevo sistema de administración específica de péptidos de penetración celular (CPP) que se aplica en el desarrollo de fármacos y tratamientos para mejorar las arrugas y en enfermedades autoinmunes y neurodegenerativas basadas en la actividad técnica. Un péptido de penetración celular consta de aproximadamente 10 a 30 aminoácidos que se translocan intracelularmente sin causar daños a las células. Los nuevos péptidos desarrollados por la empresa ofrecen una penetración celular mucho mayor incluso a una concentración más baja que otros péptidos actualmente conocidos. La empresa busca socios interesados en el desarrollo de productos farmacéuticos o biocosmecéuticos para llevar a cabo estudios no clínicos y clínicos y establecer acuerdos de cooperación técnica e investigación.

Details

Tittle:
Highly efficient Drug Delivery System (DDS) for drugs and biocosmeceuticals
Summary:
A Korean bio-venture company has developed a new specific Cell Penetrating Peptide (CPP) - cargo drug delivery system that can be applied to the development of drugs and treatments of wrinkle improvement, autoimmune disease and neurodegenerative diseases based on the technical activity. The company is looking for partners interested in the development of pharmaceuticals or bio-cosmeceuticals to carry out non-clinical and clinical studies under research and technical cooperation agreement.
Description:
Cell Penetrating Peptide (CPP) consists typically of appx. 10 to 30 amino acids, which could translocate intracellularly without causing any damages to cells. Thus they can safely deliver various desired Active Pharmaceutical Ingredients (API) including DNAs or proteins that are not cell-permeable in-nature. Despite the advantages of CPPs, challenges to utilized CPP for drug development include low transduction efficiency as well as limited cargo sizes and types.

Novel CPPs have been developed by a Korean bio-venture company established in 2000. These CPPs have much higher cell-penetrability even at a lower concentration than other CPPs known currently. In addition, they have a capability of delivering larger cargo size (~ 100 kDa) and various cargo types (proteins, siRNA, etc), blood-brain barrier (BBB) penetrability, and more divers routes of administration.

Their impressive cell-penetrability has been demonstrated in various cell lines. Upon in-vitro studies with confocal laser microscopic analysis, they had shown 10 to 20 times higher cell-penetrability than other CPPs.

In in-vivo studies, they effectively penetrate and are well-distributed into various tissues including kidney, liver, lung, heart, and spleen via its intravenous administration. In addition, they could be detected in brain, implying that they can penetrate the blood-brain barrier (BBB) and deliver anti-neurodegenerative cargoes into the brain.
They also have trans-dermal delivery capability via topical application and penetrability into retinal cells via intravitreal and sub-retinal administration.

Thus, they are applicable to a superior Drug Delivery System (DDS) to transport therapeutic APIs or cargoes based on its superior cell translocating properties. This company is currently developing various CPP-fused biologics and bio-cosmeceuticals to treat atopic dermatitis, retinal disease, and neurodegenerative diseases as well as to treat and improve wrinkles and hair growth.

Their CPPs have huge potentials for the new drug development in various rare and incurable diseases via conjugation with therapeutic agents in order to replace the pathological gene-associated or depleted intracellular proteins. With its proprietary CPPs technology, the company is actively developing lead compounds to treat Leber´s congenital amaurosis, Severe Combined Immunodeficiency (SCID) and cancer and more.

The company is looking for partners who are interested in technical cooperation to utilize their CPPs into partners´ cargo API based upon the superior cell-penetrability and tissue distribution. The cargoes can be from small to large proteins up to 100 kDa, siRNA, or other macromolecules. In addition, the company is also open to research cooperation in order to carry out non-clinical and clinical development of their proprietary CPPs utilized molecules.
Advantages and Innovations:
The company´s technology is:
- Novel CPP of new structure and properties
- Much more efficient at concentrations 10 to 20 times lower than any other well-known CPPs
- Determined to distribute in various organs (kidney, liver, lung, heart, spleen, brain, etc.) via intravenous therapy
- Transduced effectively into retina via ocular administration (intravitreal, subretinal injection and eye drop treatment)
- Confirmed superior skin permeability with topical treatment
- Applicable to drug delivery system to effectively deliver drugs or bio-cosmeceuticals
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Korean Patent Registration (2016) -Y- PCT application (2016)

Partner sought

Type and Role of Partner Sought:
- Type of partner sought: SME or large company
- Specific area of activity of the partner: Pharmaceuticals/Cosmetics
- Task to be performed: Technical cooperation for utilizing the company´s CPPs into partners´ cargo API based upon the superior cell-penetrability and tissue distribution.
Research cooperation for non-clinical and clinical development of their proprietary CPPs utilized molecules.

Client

Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English

Keywords

Technology Keywords:
06001015 Productos farmacéuticos / medicamentos